Trial Outcomes & Findings for Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa (NCT NCT02811432)
NCT ID: NCT02811432
Last Updated: 2026-01-08
Results Overview
early neonatal mortality at 7 days
COMPLETED
NA
2221 participants
7 days
2026-01-08
Participant Flow
Participant milestones
| Measure |
Intervention
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Overall Study
STARTED
|
1110
|
1111
|
|
Overall Study
COMPLETED
|
1083
|
1102
|
|
Overall Study
NOT COMPLETED
|
27
|
9
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa
Baseline characteristics by cohort
| Measure |
Kangaroo Mother Care
n=1110 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: aiming for 18 hours per day)
|
Standard Care
n=1111 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
Total
n=2221 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
1110 Participants
n=9 Participants
|
1111 Participants
n=6 Participants
|
2221 Participants
n=9 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Age, Continuous
|
20.3 hours
STANDARD_DEVIATION 11.6 • n=9 Participants
|
21.5 hours
STANDARD_DEVIATION 11.5 • n=6 Participants
|
20.9 hours
STANDARD_DEVIATION 11.6 • n=9 Participants
|
|
Sex: Female, Male
Female
|
552 Participants
n=9 Participants
|
550 Participants
n=6 Participants
|
1102 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
558 Participants
n=9 Participants
|
561 Participants
n=6 Participants
|
1119 Participants
n=9 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1110 Participants
n=9 Participants
|
1111 Participants
n=6 Participants
|
2221 Participants
n=9 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Region of Enrollment
Uganda
|
1110 participants
n=9 Participants
|
1111 participants
n=6 Participants
|
2221 participants
n=9 Participants
|
PRIMARY outcome
Timeframe: 7 daysearly neonatal mortality at 7 days
Outcome measures
| Measure |
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1102 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Mortality Within 7 Days
|
81 Participants
|
83 Participants
|
SECONDARY outcome
Timeframe: 24 hoursPrevalence of hypothermia at 24 hours post-randomisation using axillary temperature was assessed using a digital thermometer.
Outcome measures
| Measure |
Intervention
n=1096 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1101 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Prevalence of Hypothermia at 24 Hours Post-randomisation
|
448 participants
|
585 participants
|
SECONDARY outcome
Timeframe: 30 daysTime-to-stabilization was defined as the first time at which a neonate had met all of the following criteria for a continuous period of at least 24 hours: breathing spontaneously with SpO2 \>90% in room air; no need for supplemental oxygen or CPAP; respiratory rate 40-59 breaths per minute; no apneic episodes; heart rate 80-179 beats per minute; axillary temperature 36.0-37.4 °C; and no need for intravenous fluids.
Outcome measures
| Measure |
Intervention
n=1081 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1100 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Time From Intervention/Control Procedures Starting to Clinical Stabilisation
|
5.1 days
Interval 4.1 to 6.7
|
4.9 days
Interval 3.8 to 6.5
|
SECONDARY outcome
Timeframe: 30 daysThe date and time of death were prospectively recorded from the death certificate for in-hospital deaths. For deaths occurring after discharge, the date was recorded based on parent/caregiver verbal report. Median and IQR of time-to-event calculated as the 50th and 25th to 75th percentile of the distribution of event times among those who experienced the event.
Outcome measures
| Measure |
Intervention
n=119 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=134 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Time From Starting Intervention/Control Procedures to Death
|
5.0 hours
Interval 2.5 to 10.7
|
5.9 hours
Interval 2.8 to 13.9
|
SECONDARY outcome
Timeframe: 30 daysPopulation: at the 28-30 day visit
The date and time of hospital admission and discharge were documented prospectively for the first admission episode.
Outcome measures
| Measure |
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1102 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Mean Duration of Hospital Stay in Days
|
7.3 days
Standard Error 0.15
|
6.1 days
Standard Error 0.14
|
SECONDARY outcome
Timeframe: 30 daysProportion of neonates who were exclusively breastmilk feeding at discharge, from the breast or by other means
Outcome measures
| Measure |
Intervention
n=1083 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1102 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Proportion of Neonates Exclusively Breastmilk Feeding at Discharge
|
959 Participants
|
978 Participants
|
SECONDARY outcome
Timeframe: 28 daysAll-cause mortality within 28 days. Vital status was documented at the 28-30-day follow-up visit. If participants did not attend, a telephone call was made the same day to ascertain outcome.
Outcome measures
| Measure |
Intervention
n=1051 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1049 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Mortality Within 28 Days
|
119 Participants
|
134 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: by 28-30 day visit
Episodes in which a neonate was readmitted to the index hospital were prospectively recorded. Episodes in which a neonate was readmitted to a different hospital were recorded based on parent/caregiver verbal report.
Outcome measures
| Measure |
Intervention
n=848 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=840 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Frequency of Readmission
|
0.02 readmission count
Standard Error 0.01
|
0.04 readmission count
Standard Error 0.01
|
SECONDARY outcome
Timeframe: 28 daysPopulation: by 28-30 day visit
Mean daily weight gain was calculated as the difference between weight at enrollment and 28-30-day follow-up, as measured by the study scale.
Outcome measures
| Measure |
Intervention
n=761 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=731 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Daily Weight Gain at 28 Days
|
7.8 g/kg/day
Standard Error 0.3
|
7.1 g/kg/day
Standard Error 0.3
|
SECONDARY outcome
Timeframe: 28 daysPopulation: day 28-30 visit
The intention-to-treat analysis assessed the mean difference in Maternal Infant Responsiveness Instrument score between the two arms. Scores range from 0 to 110, with higher scores indicating greater attachment.
Outcome measures
| Measure |
Intervention
n=758 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=725 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Infant-caregiver Attachment at 28 Days
|
85.4 MIRA score
Standard Error 0.28
|
85.0 MIRA score
Standard Error 0.28
|
SECONDARY outcome
Timeframe: 28 daysPopulation: at the 28-30 day visit
The intention-to-treat analysis assessed the mean difference in Women's Capabilities Index (WCI) score between the two arms. The WCI has a scale of 0 to 1, with higher scores indicating greater wellbeing. The analysis excluded duplicate entries for mothers of enrolled twins/triplets.
Outcome measures
| Measure |
Intervention
n=624 Participants
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=602 Participants
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Women's Well-being at 28 Days
|
0.69 WCI score
Standard Error 0.01
|
0.68 WCI score
Standard Error 0.01
|
Adverse Events
Intervention
Control
Serious adverse events
| Measure |
Intervention
n=1051 participants at risk
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1049 participants at risk
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Blood and lymphatic system disorders
SAEs and other adverse events
|
0.76%
8/1051 • Number of events 8 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.95%
10/1049 • Number of events 10 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Cardiac disorders
SAEs and other adverse events
|
0.00%
0/1051 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.10%
1/1049 • Number of events 1 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Gastrointestinal disorders
SAEs and other adverse events
|
1.1%
12/1051 • Number of events 12 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.67%
7/1049 • Number of events 7 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Respiratory, thoracic and mediastinal disorders
SAEs and other adverse events
|
5.6%
59/1051 • Number of events 59 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
6.0%
63/1049 • Number of events 63 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Hepatobiliary disorders
Neonatal jaundice
|
0.38%
4/1051 • Number of events 4 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.57%
6/1049 • Number of events 6 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.10%
1/1051 • Number of events 1 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.00%
0/1049 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Nervous system disorders
Neurological disorders
|
0.76%
8/1051 • Number of events 8 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.86%
9/1049 • Number of events 9 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
Infections and infestations
neonatal infections
|
3.2%
34/1051 • Number of events 34 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
3.3%
35/1049 • Number of events 35 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
|
General disorders
Hyperthermia
|
0.00%
0/1051 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
0.19%
2/1049 • Number of events 2 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
Other adverse events
| Measure |
Intervention
n=1051 participants at risk
Skin-to-skin care initiated as soon as possible following randomisation
Kangaroo mother care: Skin-to-skin care (target: at least 18 hours per day)
|
Control
n=1049 participants at risk
Incubator or radiant warmer
Standard care: Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
|
|---|---|---|
|
Hepatobiliary disorders
Neonatal jaundice
|
17.1%
180/1051 • Number of events 180 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
8.6%
90/1049 • Number of events 90 • 28 days of age
The site paediatrician was informed about SAEs within 24 h. SAEs were followed up by the site paediatrician until resolution, or until causality was determined as unrelated to the trial intervention. If an unexpected SAE occurred, potentially related to the trial intervention, a report was submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48h, with a follow-up report provided. All SAEs were reported to Sponsor and DSMB as part of their respective reports.
|
Additional Information
Professor Joy Lawn
London Sch Hygiene & Trop Medicine -
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place